There’s a fundamental shift underway in the pharmaceutical industry. One that’s exposing the challenges of our current product-first, indication-specific mindset and forcing us to shift our paradigm. The cause of this disruption is the phenomenal rise of GLP-1 receptor agonists like semaglutide, compounds with the potential to revolutionize treatment across multiple therapeutic areas.
And yet, with that promise comes complexity.
GLP-1s were originally developed and approved to help manage blood sugar in people with Type 2 diabetes. But what began as a metabolic therapy has now evolved into something much bigger. Brands like Ozempic, deeply embedded in the science and prescribed by physicians, have suddenly found themselves in very uncertain territory.
The explosion of interest has sparked a cultural phenomenon that extends far beyond the clinic, igniting a global weight loss craze fueled by celebrity endorsements, TikTok testimonials, and a tidal wave of media coverage. “Ozempic isn’t just a medication, it’s become a movement,” noted Dr. Katherine Saunders, an obesity specialist at Weill Cornell. As Dr. Scott Kahan put it, “It’s rare for a drug to so thoroughly enter the cultural zeitgeist.” Ozempic and its cousins aren’t just changing waistlines. They’re reshaping the conversation about health, identity, and pharmaceutical branding.
This is creating a conundrum for companies like Novo Nordisk that has a specific brand, Ozempic’s sibling Wegovy, positioned specifically for weight management. There are likely internal challenges to ensure one brand doesn’t cannibalize the other, while opening the aperture for other expansive opportunities. And this is just the beginning. As we know, these molecules are already being explored, and in some cases already indicated, for obesity, cardiovascular risk reduction, NASH, and even neurodegenerative conditions like Alzheimer’s.
Many brand teams, across our clients, are finding themselves navigating a new kind of internal and external tension: how to market a single molecule that delivers therapeutic value across multiple, seemingly unrelated disease states.
Do you lean into its original indication? Reframe it around its highest-growth opportunity? Or build entirely new brands for each use case?
This isn’t just a messaging challenge. It’s a strategic reckoning for an industry built on a linear pipeline: one drug, one disease, one specialty, one story.
GLP-1s are breaking that model. And they’re not the exception; they’re the bellwethers of the future.
A New Kind of Problem for a New Kind of Molecule
GLP-1s are a textbook example of what Clayton Christensen called “disruptive innovation.” Originally designed to treat Type 2 diabetes by regulating insulin and blood sugar levels, these compounds have proven effective for obesity, cardiovascular risk reduction, and potentially even Alzheimer’s and non-alcoholic steatohepatitis (NASH). A single molecule has demonstrated efficacy across at least five distinct disease states. And there are early signals of efficacy in others, including addiction and mood disorders.
But the pharmaceutical playbook wasn’t written for drugs like this.
Historically, pharma has followed a fairly linear formula:
- Identify a molecule that solves a narrowly defined biological problem.
- Prove its efficacy in a targeted population.
- Build a brand around that singular purpose.
- Sell it through a combination of medical education and physician-led access strategies.
It’s a pipeline model designed for precision, and for good reason. But when you have a molecule that is inherently polyfunctional and can address interrelated metabolic, neurological, and inflammatory pathways, this model starts to fracture.
You’re no longer marketing a product. You’re managing a platform. And that requires a different kind of thinking.
From Selling a Chemical to Building Brand Chemistry
To move forward, we need to shift from a mindset of chemical specificity to one of brand chemistry. That is, not just understanding what a molecule does in the body, but what it means in the mind. Because positioning isn’t about what you do to a product, but rather what you do to the mind of the prospect. It’s about translating molecular function into human relevance—emotional resonance, perceived value, and real-world outcomes.
This isn’t a foreign concept. Consumer brands have been leveraging it for decades.
Take toothpaste. Nearly every leading brand, from Colgate to Crest to Sensodyne, relies on the same base chemical: fluoride, a compound scientifically proven to reduce tooth decay by strengthening enamel and remineralizing early lesions. Yet fluoride alone doesn’t create preference. Colgate doesn’t sell fluoride. It has Colgate Total for whole-mouth health, Optic White for brighter smiles, and Sensitive Pro-Relief for pain relief. All from the same molecular foundation. They have built billion-dollar franchises by tapping into specific consumer needs, desires, fears, and aspirations.
This is the opportunity for pharma. As molecules like semaglutide span multiple indications and therapeutic areas, brand builders must stop asking “what does the drug do” and start asking “what does it enable?” What story does it tell? What identity does it support? And how can we tailor that meaning to match the unique needs, both rational and emotional, of the people we serve?
In an era where scientific innovation is replicable, brand chemistry is the one true competitive advantage.
Why Hasn’t Pharma Done the Same?
The answer lies partly in regulation, partly in tradition, but mostly in a failure to reframe. Clinical trials are run at the molecular level. Brands are built at the indication level. And medical professionals are trained in therapeutic silos, where endocrinologists manage diabetes, bariatric specialists manage obesity, cardiologists manage heart health, and neurologists manage dementia and so forth.
So, when a single molecule has clinical relevance across all these areas, we don’t know where to put it. The system isn’t designed to support cross-functional brand narratives.
Yet.
Should We Build One Superbrand or Many Targeted Brands?
This is the strategic fork in the road for pharma today.
Option A: Build a single masterbrand around the molecule. A cross-therapy platform that positions it as a Swiss army knife for metabolic and inflammatory disease.
Option B: Create a family of targeted sub-brands, each optimized for a specific therapeutic domain, tailored to the needs of specialists and patients in that space.
Both approaches have merit.
A masterbrand could drive halo effects across indications, simplify messaging, and accelerate awareness, especially in a world where consumer influence on therapy choice is rising. It aligns with how the public already sees semaglutide: as a wonder drug that does it all.
But this strategy risks diluting clinical credibility. Physicians expect precision. Specialists don’t want an all-purpose drug. A cardiologist doesn’t want a “weight loss drug.” A neurologist won’t prescribe a “diabetes medication.” They want peer-reviewed evidence, real-world data, and specific mechanisms of action.
Which brings us back to the importance of building brands. We’re not just talking about naming or packaging; we’re talking about framing: the art of connecting what a molecule does to what a human being needs in a specific context.
The Consumerization of Healthcare Demands Human-Centered Framing
Patients aren’t waiting for the industry to catch up. They’re searching for symptoms online, joining Reddit forums, and watching TikTok reviews. In the age of radical transparency, brand meaning is shaped as much by memes and influencers as by peer-reviewed journals.
In that world, brand purpose matters. Emotional value matters. Why the pharma industry must start thinking more like consumer marketers.
Let’s borrow a page from the automotive industry. BMW, Mercedes, and Volvo all make safe, high-performance, luxury cars. But each owns a different brand value proposition in the consumer’s mind:
- BMW = performance and driving joy.
- Mercedes = luxury and status.
- Volvo = safety and peace of mind.
The differences aren’t always overtly evident. They’re focused on delivering on very specific needs of different segments in alignment with their customers’ values.
In pharma, we’re only beginning to tap into this idea. What if semaglutide wasn’t just a “drug”? What if it was a platform that fulfilled the specific needs of different segments? Each with its own brand story, emotional resonance, and clinical context?
- For the busy executive trying to regain control of their weight: a brand that promises energy, confidence, and performance.
- For the cardiovascular patient: a brand that symbolizes proactive prevention and long-term heart health.
- For the family of an Alzheimer’s patient: a brand that offers hope, backed by science, for slowing cognitive decline.
Same molecule. Different brands. Tailored frames. Shared backbone.
From Products to Regimens. Embracing the New Role of Combination.
Another unlock lies in how we think about treatment regimens.
Traditionally, pharma brands have vied for primacy: each brand wants to be the leader. The one used in first line. But what if we shifted the frame from just replacing the incumbent of its therapeutic area? What if our brand can be an integrator?
The multiple myeloma market has an example. In contrast to the paradigm of primacy that other brands attempted, Darzalex (daratumumab) didn’t try to own the entire treatment pathway. Instead, it built its positioning around its role in a broader combination regimen. It was marketed not as the solution, but as a critical part of the solution. This integrative approach, leveraging its precision, has earned it a dominant position in its market.
In the world of GLP-1s, a similar path may emerge. Rather than battling for solo dominance in every therapeutic area, brands can define themselves by the role they play within a regimen.
What Pharma Can Learn from Platform Thinking
This is a mindset shift. Pharma has long been product-focused. But in a world of polyfunctional drugs and converging pathologies, we also need platform thinking.
Think Apple. The iPhone isn’t just a phone. It’s a platform for communication, productivity, entertainment, and health. Apple doesn’t sell silicon. It sells a lifestyle.
Think Tesla. It doesn’t just sell electric cars. It sells sustainable performance, with a digital-first customer experience.
Think Amazon. It started as a bookstore. It became a commerce infrastructure. Today, it’s a platform for everything from groceries to cloud computing.
Pharma can do the same. It just requires one radical act: stop thinking of drugs as endpoints. Start thinking of them as enablers. Enablers of outcomes. Enablers of stories. Enablers of longer lives. Enablers of lives worth living.
Chemicals + Human Chemistry
So, what’s the way forward?
- Segment not just by disease, but by human need. Build brand expressions that speak to both clinical and emotional goals. Diabetes isn’t just about A1C. Obesity isn’t just about BMI. Alzheimer’s isn’t just about plaques. They’re all about the overall quality of life.
- Define brand roles, not just product benefits. Are you the hero? The guide? The enabler? Position the molecule within the regimen, the journey, and the emotional arc of the patient experience.
- Embrace modular branding. One molecule. Multiple use-cases. A clear architecture that connects them all. Think iPad, iPad Mini, iPad Pro—not just “the iPad.”
- Co-create with HCPs across silos. Break the walls between specialties. Encourage data sharing, cross-functional advisory boards, and shared language. Build the platform together.
- Activate new channels in new ways. Not just to drive demand, but to drive understanding. Use storytelling to reframe how people see the brand. Meet them where they are (TikTok, YouTube, patient forums) and elevate the discourse.
- Think beyond the pill. What digital tools, services, or support ecosystems can enhance the brand experience? What behaviors can you enable, not just conditions you can treat?
The Future Belongs to Brands With Meaning
We are entering an era where the most valuable molecules are not those that treat the narrowest diseases but those that can serve the broadest human needs.
To thrive in this future, we must stop thinking only about selling chemicals and build brand chemistry, the alchemy of molecule, message, and meaning that turns clinical science into huge human impact.
The companies that embrace this shift will no longer just launch drugs. They’ll lead movements.
And that’s the kind of future worth building.